Search Results
Results found for "Omass Therapeutics"
- 📰 GPCR Weekly News, May 15 to 21, 2023
Hopkins, Exscientia’s founder and CEO was elected a Fellow of the Academy of Medical Sciences Structure Therapeutics
- Understanding Enzyme Inhibition In GPCR Discovery Programs
When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design.
- Unveiling GPCR Priming: The Hidden Synergy in Cellular Signalling
implications for drug development, as targeting these non-cognate interactions could lead to novel therapeutic
- 📰 GPCR Weekly News, March 18 to 24, 2024
Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease (IBD) Domain Therapeutics
- 📰 GPCR Weekly News - January 2 to 8, 2023
Enter into Multitarget Antibody Discovery Research Collaboration Neurocrine Biosciences and Voyager Therapeutics
- GPCR Collaboration: From Models to Medicine
They offer extraordinary therapeutic promise —but their complexity makes them one of the hardest targets
- Interacting binding insights and conformational consequences of the differential activity of...
way for understanding the CBD pharmacology at a molecular level and aid in harnessing its potential therapeutic
- Drug Discovery Pharmacology Principles That Turn Assays Into Real Medicines
Kenakin highlights that therapeutic efficacy depends on the period during which a drug is actively engaged
- The Hidden Cost of Ambition in Biotech Leadership
A strong preclinical signal opens adjacent therapeutic areas.
- Dr. GPCR University registration is now open! Secure your spot now!
the atomic-level quaternary structure of short-lived GPCR oligomers in live cells Industry News Confo Therapeutics
- Decoding β-Arrestins: from Structure to function
M. et al. 2019), and hydrogen-deuterium exchange (HDX) mass spectrometry for time-dependent conformational within distinct cell types or tissues, will undoubtedly provide valuable guidance for advancing such therapeutic
- Advantages of Fluorescent Probes in GPCR Assays
GPCRs pose a critical challenge in drug discovery: a vast therapeutic potential with many targets yet
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
competitive edge: Learn to leverage restricted diffusion and rebinding to create drugs with longer therapeutic
- 📰 GPCR Weekly News, October 16 to 22, 2023
potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology, Domain Therapeutics
- FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
4️⃣ Comparative value: Have you positioned your therapeutic against the right standard or competitor,
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively activate therapeutically analyzing drug-target interactions and disease pathways, AI can identify potential candidates that may have therapeutic
- 📰 GPCR Weekly News, December 4 to 10, 2023
Muscarinic Agonist Candidates in Phase 1 Clinical Studies AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
understanding how serotonin receptors, one of the largest subfamilies of class A GPCRs and potential therapeutic
- 📰 GPCR Weekly News - January 9 to 15, 2023
Foundation is awarding DKK 174 million in grants to seven ‘mind-bending’ research collaborations GPCR Therapeutics
- 📰 GPCR Weekly News, November 6 to November 12, 2023
Jefferies Healthcare Conference in London Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic
- Competitive vs Non-Competitive GPCR Antagonists: How to Interpret Pharmacology Data with Confidence
Essential Frameworks for Precision Drug Discovery: An Insight into Advanced Strategies for Targeted Therapeutics
- 📰 GPCR Weekly News, February 5 to 11, 2024
Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 Domain Therapeutics
- A2A Fluorescent Competitive Binding: Advancing NanoBRET® Target Engagement for GPCR Drug Discovery
Introduction to Adenosine Receptors as Therapeutic Targets.
- 📰 GPCR Weekly News, January 8 to 14, 2024
MCF7 breast cancer cells Reviews, GPCRs, and more The multifaceted functions of β-arrestins and their therapeutic
- From Failed Experiments to Predictive GPCR Models
increasingly depend on those who can unite modeling with experimentation, turning predictions into real therapeutic
- HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G 1/S cycle
modulating autophagy and the CDKN1B-CDK2-CCNE1-E2F1 axis and indicate that ARRB1 may be a potential therapeutic
- 📰 GPCR Weekly News, March 6 to 12, 2023
Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
20th World Congress of Basic and Clinical Pharmacology GPCR Jobs Scientist I Cell Biology - Tectonic Therapeutic
- 📰 GPCR Weekly News, June 17 to 23, 2024
and triterpenes isolated from Cryptostegia grandiflora against Candida auris FKBP12 Development and therapeutic
- 📰 GPCR Weekly News, April 24 to 30, 2023
GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics












